Clinical Trials Logo

B-Cell Non-Hodgkin Lymphoma clinical trials

View clinical trials related to B-Cell Non-Hodgkin Lymphoma.

Filter by:

NCT ID: NCT04296461 Recruiting - Clinical trials for B-cell Non-Hodgkin Lymphoma

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Start date: July 27, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).

NCT ID: NCT04257578 Recruiting - Clinical trials for B-Cell Non-Hodgkin Lymphoma

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

Start date: December 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma.

NCT ID: NCT04191941 Recruiting - Multiple Myeloma Clinical Trials

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Start date: September 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.

NCT ID: NCT04148430 Active, not recruiting - B-Cell Lymphoma Clinical Trials

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Start date: October 30, 2019
Phase: Phase 2
Study type: Interventional

This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.

NCT ID: NCT04088890 Active, not recruiting - DLBCL Clinical Trials

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Start date: September 12, 2019
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).

NCT ID: NCT04030195 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Start date: March 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.

NCT ID: NCT03870945 Active, not recruiting - Clinical trials for B-cell Non Hodgkin Lymphoma

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Start date: February 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

NCT ID: NCT03778073 Terminated - Clinical trials for B-cell Non Hodgkin Lymphoma

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

NCT ID: NCT03704714 Suspended - Clinical trials for B-Cell Non-Hodgkin Lymphoma

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Start date: November 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.

NCT ID: NCT03677141 Completed - Clinical trials for B-cell Non-Hodgkin Lymphoma

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Start date: March 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).